Michael Buckstein, MD, PhD

Clinical Focus

• Anal Cancer
• Colorectal Cancer
• Esophageal Cancer
• Gallbladder Cancer
• Liver Cancer
• Pancreatic Cancer
• Radiation Therapy

• Anal Cancer
• Colorectal Cancer
• Esophageal Cancer
• Gallbladder Cancer
• Liver Cancer
• Pancreatic Cancer
• Radiation Therapy

Research

Locations

FPA/Radiation Oncology Associates

1184 Fifth Ave. 1st Floor, Box 1236, New York, NY, 10029

212-241-7502

Insurance Information

Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Publications

Scopus h-index:17

Article:44

Review Article:4

Comment/Debate:4

Letter:3

Editorial:3

Selected Publications

• Hits and Misses in Novel Pancreatic and Rectal Cancer Treatment Options
• The Rise of Open Access Journals in Radiation Oncology: Influence on Resident Research, 2015 to 2019
• Clinical and treatment characteristics of secondary bladder malignancies following low dose rate brachytherapy for prostate cancer
• What Rectal Cancer Patients May Be Able to Safely Avoid Radiation?
• Combination Transarterial Chemoembolization and Stereotactic Body Radiation Therapy for Unresectable Single Large Hepatocellular Carcinoma: Results From a Prospective Phase 2 Trial
• Oligoprogression of Solid Tumors on Immune Checkpoint Inhibitors: The Impact of Local Ablative Radiation Therapy
• Author Correction: Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery (Nature Medicine, (2022), 28, 4, (626-629), 10.1038/s41591-022-01681-x)
• Characterization and Prediction of Signal Intensity Changes in Normal Liver Parenchyma on Gadoxetic Acid–enhanced MRI Scans after Liver-directed Radiation Therapy
• CROSSing into New Therapies for Esophageal Cancer
• Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Buckstein did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.